Analyst Price Target is $324.86
▲ +21.33% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is $324.86, with a high forecast of $350.00 and a low forecast of $270.00. The average price target represents a 21.33% upside from the last price of $267.75.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Penumbra. This Buy consensus rating has held steady for over two years.
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.